Medlander (688273.SH) Reports 2022 Net Profit of RMB 123 Million, Up 3.93% Year-over-Year

Medlander (688273.SH) released its 2022 annual earnings快报. During the reporting period, the company's total operating revenue was 377 million yuan, representing a year-on-year increase of 10.28%; operating profit was 149 million yuan, up 14.44% year-on-year; total profit amounted to 149 million yuan, a year-on-year increase of 14.71%; net profit attributable to the parent company’s owners was 123 million yuan, an increase of 3.93% year-on-year; net profit attributable to the parent company’s owners excluding non-recurring gains and losses was 89.2509 million yuan, a year-on-year decrease of 14.70%.

The main reasons for the company's performance growth during the reporting period are as follows: First, the company adheres to innovation-driven development and continues to invest in new product research and development. This year, the company launched new products in the pelvic floor diagnosis and treatment series and new products in female reproductive rehabilitation equipment, providing new momentum for performance growth; Second, the company's non-recurring gains and losses increased during the reporting period compared to the previous year, mainly due to: a) Growth in idle fund management income; b) Government funding support received by the company for undertaking national key R&D projects and provincial critical core technology (equipment) tackling projects.